Corticotropin-releasing hormone

Corticotropin-releasing hormone (CRH), also known as corticotropin-releasing factor (CRF), is a peptide hormone involved in the stress response. It is a critical component of the hypothalamic-pituitary-adrenal axis (HPA axis) and plays a significant role in coordinating the body's response to stress by regulating the release of adrenocorticotropic hormone (ACTH) from the pituitary gland. ACTH, in turn, stimulates the adrenal cortex to produce glucocorticoids, such as cortisol, which have various effects on metabolism, immune function, and other physiological processes.

Structure and Function

CRH is composed of 41 amino acid residues, making it a relatively small peptide. It is synthesized in the paraventricular nucleus of the hypothalamus and is released into the portal system of the pituitary gland, where it binds to CRH receptors on the anterior pituitary cells, triggering the release of ACTH.

The CRH gene is located on chromosome 8 in humans and is regulated by various factors, including stress, physical activity, and diurnal rhythms. Its expression and release are increased by stress, leading to higher levels of ACTH and cortisol, which help the body manage and adapt to stress.

Clinical Significance

CRH plays a role in several conditions related to stress and the HPA axis. Dysregulation of CRH secretion has been implicated in mood disorders such as depression and anxiety, as well as in chronic stress and post-traumatic stress disorder (PTSD). Elevated levels of CRH have been found in the cerebrospinal fluid of patients with depression, suggesting a hyperactive HPA axis.

In addition to its role in stress and mood disorders, CRH testing can be used in the diagnosis of Cushing's syndrome, a condition characterized by excessive cortisol production. The CRH stimulation test involves administering synthetic CRH and measuring the pituitary gland's response in terms of ACTH and cortisol levels. A blunted response is indicative of Cushing's syndrome.

Pharmacology

CRH receptor antagonists are being explored as potential treatments for depression, anxiety, and other stress-related disorders. By blocking the action of CRH, these drugs aim to reduce the overactivation of the HPA axis seen in these conditions. However, the development of CRH antagonists has been challenging, and more research is needed to understand their therapeutic potential fully.

See Also

• Adrenocorticotropic hormone
• Hypothalamic-pituitary-adrenal axis
• Cushing's syndrome
• Stress

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian